


## Methyl eugenol

## Chemical Properties

CAS No. :	93-15-2
Formula:	C <sub>11</sub> H <sub>14</sub> O <sub>2</sub>
Molecular Weight:	178.23
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years   In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



## Biological Description

Description	<p>1. Methyl eugenol (4-allylveratrole) is a natural constituent of the essential oils of a number of plants widely used in foodstuffs as flavouring agents, in view of the carcinogenic potential of ME, the need to check its presence in food products with effective analytical methods. 2. Methyleugenol has insecticidal properties. 3. Methyleugenol can inhibit the production of nitric oxide and decreased the protein expression of inducible nitric oxide synthase, it down-regulates the production of pro-inflammatory cytokines in the ischemic brain as well as in immunostimulated mixed glial cells; indicates that methyleugenol could be useful for the treatment of ischemia/inflammation-related diseases. 4. Methyleugenol has cytotoxicity and genotoxicity. 5. Intravenous (i.v.) treatment with methyleugenol (ME) in either anesthetized or conscious rats elicits hypotension, an effect that seems related to an active vascular relaxation rather than withdrawal of sympathetic tone. 6. Methyleugenol has antinociceptive effect on the second phase of formalin-induced pain, may be due to the inhibition of N-methyl-d-aspartic acid (NMDA) receptor-mediated hyperalgesia via GABA(A) receptors. 7. Methyleugenol has elaxant and antispasmodic actions on guinea-pig isolated ileum.</p>
Targets(IC50)	Akt,GABA Receptor,Autophagy,mTOR,PI3K

## Solubility Information

Solubility	DMSO: 250 mg/mL (1402.68 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	<p>10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (11.22 mM),Sonication is recommended.</p> <p><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i></p>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	5.6107 mL	28.0536 mL	56.1073 mL
5 mM	1.1221 mL	5.6107 mL	11.2215 mL
10 mM	0.5611 mL	2.8054 mL	5.6107 mL
50 mM	0.1122 mL	0.5611 mL	1.1221 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Choi Y K , Cho G S , Hwang S , et al. Methyleugenol reduces cerebral ischemic injury by suppression of oxidative injury and inflammation[J]. Free Radical Research, 2010, 44(8):925-935.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481